Progyny, Inc. (NASDAQ:PGNY – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $48.11.
A number of research firms recently issued reports on PGNY. Cantor Fitzgerald lifted their target price on Progyny from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, September 14th. JPMorgan Chase & Co. lowered their target price on Progyny from $58.00 to $57.00 and set an “overweight” rating on the stock in a report on Monday, October 9th. Truist Financial increased their price target on Progyny from $48.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, August 11th. KeyCorp increased their price target on Progyny from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Finally, Canaccord Genuity Group started coverage on Progyny in a research report on Wednesday, September 27th. They issued a “buy” rating and a $46.00 price target for the company.
Hedge Funds Weigh In On Progyny
Progyny Stock Up 3.5 %
NASDAQ:PGNY opened at $31.90 on Monday. The business’s 50-day moving average price is $33.97 and its 200 day moving average price is $36.54. The firm has a market cap of $3.04 billion, a P/E ratio of 65.10, a PEG ratio of 1.38 and a beta of 1.53. Progyny has a 52-week low of $28.03 and a 52-week high of $44.95.
Progyny (NASDAQ:PGNY – Get Free Report) last released its earnings results on Thursday, August 3rd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.05. The firm had revenue of $279.40 million for the quarter, compared to analyst estimates of $261.91 million. Progyny had a return on equity of 12.19% and a net margin of 5.15%. Progyny’s revenue was up 43.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.09 earnings per share. Sell-side analysts expect that Progyny will post 0.53 EPS for the current year.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Five stocks we like better than Progyny
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 10/30 – 11/3
- Large Cap Stock Definition and How to Invest
- Shocking uranium play that hedge funds kept hidden
- Canada Bond Market Holiday: How to Invest and Trade
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.